a public good project by the
Synthesis
Company
of California

© 2026

Jens J. Holst | doi.page

0 works0 citations0 h-index

Jens J. Holst

University of Copenhagen(DK)Novo Nordisk Foundation(DK)

Publications by Year

Research Areas

Diabetes Treatment and Management, Pancreatic function and diabetes, Diet and metabolism studies, Diabetes Management and Research, Metabolism, Diabetes, and Cancer

Most-Cited Works

→ The Physiology of Glucagon-like Peptide 1(2007)3,192 cited
→ Type 2 diabetes mellitus(2015)2,463 cited
→ Glucagon-like peptide 1 (GLP-1)(2019)1,649 cited
→ Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.(1993)1,635 cited
→ Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.(1998)1,381 cited
→ Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study(2002)1,296 cited

→ Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients(1993)

1,087 cited

→ Switching from Insulin to Oral Sulfonylureas in Patients with Diabetes Due to Kir6.2 Mutations(2006)981 cited

→ Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition(2017)980 cited

→ Inhibition of gastric inhibitory polypeptide signaling prevents obesity(2002)943 cited